Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?

Thorac Cancer

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Published: November 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336	PMC
http://dx.doi.org/10.1111/1759-7714.14641	DOI Listing

Publication Analysis

Top Keywords

adjuvant immunotherapy

immunotherapy standard

standard non-pathological

non-pathological complete

complete response

response patients

patients resectable

resectable esophageal

esophageal squamous

squamous cell

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!